- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 261 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,851
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
- Interventions
- [18F]F-AraG
- Drug
- Lead sponsor
- CellSight Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Stanford, California • Portland, Oregon
- Conditions
- Cancer
- Interventions
- 64-Cu-plerixafor
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Interventions
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
- Drug · Device · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Schizophrenia, Schizoaffective Disorder, Healthy
- Interventions
- 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor, PET Scan
- Drug · Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
- Interventions
- Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
- Procedure · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • New Haven, Connecticut
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Camonsertib, Computed Tomography, Positron Emission Tomography, Stereotactic Body Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 3
- States / cities
- Duarte, California • Irvine, California • Pittsburgh, Pennsylvania
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Interventions
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Radiation · Other · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 1,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Concussion, Brain
- Interventions
- NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
- Diagnostic Test
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Interventions
- 18F-FDOPA, 11C-DASB
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm, Nerve Sheath Neoplasms, Nerve Sheath Tumor, Nos, Solid Tumor, Adult, Solid Carcinoma
- Interventions
- [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease
- Interventions
- [18F]-FEOBV Radiotracer
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 30 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease
- Interventions
- PSMA PET/CT scan
- Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, PET, INRT, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
- Drug · Diagnostic Test · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California • Reading, Pennsylvania
- Conditions
- PTSD
- Interventions
- Placebo, Paroxetine, Positron Emission Tomography (PET) Imaging
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Dementia
- Interventions
- [18F]RP-115 PET/MRI or PET/CT and MRI
- Drug
- Lead sponsor
- David Wilson
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Interventions
- Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Pheochromocytoma, Endocrine Disease, Endocrine Diseases
- Interventions
- ([18F]-DOPA), ([18F]-6F-DA)
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 120 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2048
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 70 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 326
- States / cities
- Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 256 more
- Conditions
- Melanoma
- Interventions
- fludeoxyglucose F 18, Positron emission tomography-computed tomography, 18F-fluorothymidine, Positron emission tomography-magnetic resonance imaging
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri